Patent Grant
10793554
The present disclosure relates to pharmaceutical compositions, including solid forms of a certain compound useful for inhibiting fatty acid synthase (FASN).
Chemical compounds can form one or more different pharmaceutically acceptable solid forms, such as various polymorph crystal forms. Individual solid forms of bioactive chemical compounds can have different properties. There is a need for the identification and selection of appropriate solid forms of bioactive chemical compounds (including appropriate crystalline forms, where applicable) for the development of pharmaceutically acceptable dosage forms for the treatment of various diseases or conditions.
The compound, (4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone (Compound 1), is a small molecule inhibitor of fatty acid synthase (FASN):
Compound 1 is disclosed in PCT Application Publication No. WO 2014/164749 as one of many compounds suitable as small molecule inhibitors of FASN.
Therapeutic compounds often exist in a variety of solid forms having different properties. There remains a need for identifying solid forms of Compound 1 useful for various therapeutic applications.
Novel solid forms of Compound 1 disclosed herein include Form B, Form C, and Form X, as well as compositions comprising a solid form of Compound 1 comprising one or more of Form B, Form C, Form X and Form Z. In addition, a novel mixture of solid forms of Compound 1, Mixture A, is disclosed herein, as well as compositions comprising Mixture A.
A novel Compound 1 Mixture A can be identified by X-ray Powder Diffraction (XRPD), having one or more characteristic diffractions at angles (2 theta±0.2) of 9.6, 10.1, 15.4, 19.6, and 22.3. A novel Compound 1 Mixture A can be identified by XRPD having characteristic diffractions at angles (2 theta±0.2) of 9.6, 10.1, 15.4, 19.6, and 22.3, and not having a characteristic diffraction at angle (2 theta±0.2) of 24.2. A novel Compound 1 Mixture A can be identified (i) by differential scanning calorimetry (DSC) having two endotherms at 226.2° C. and 229.1° C.; and (ii) by XRPD having one or more characteristic diffractions at angles (2 theta±0.2) of 9.6, 10.1, 15.4, 19.6, and 22.3.
A novel Compound 1 Form B can be identified by XRPD, having one or more characteristic diffractions at angles (2 theta±0.2) of 9.6, 10.1, 15.4, 19.6, and 22.3. A novel Compound 1 Form B can be identified by XRPD, having one or more characteristic diffractions at angles (2 theta±0.2) of 9.6, 10.1, 15.4, 19.6, and 22.3, and not having one or more characteristic diffractions at angles (2 theta±0.2) of 7.2, 8.4, 14.9, 16.1, and 17.8 and/or not having a characteristic diffraction at angle (2 theta±0.2) of 24.2. A novel Compound 1 Form B can be identified (i) by DSC having one endotherm at 225.7° C.; and (ii) by XRPD having one or more characteristic diffractions at angles (2 theta±0.2) of 9.6, 10.1, 15.4, 19.6, and 22.3.
A novel Compound 1 Form C can be identified by XRPD, having one or more characteristic diffractions at angles (2 theta±0.2) of 9.6, 10.1, 15.4, 19.6, 22.2, and 26.6.
A novel Compound 1 Form X can be identified by XRPD, having one or more characteristic diffractions at angles (2 theta±0.2) of 7.2, 8.4, 14.9, 16.1, and 17.8.
A novel Compound Form Z can be identified by XRPD, having characteristic diffraction at angles (2 theta) as exemplified in
The Applicant has also discovered that novel Compound 1 solid forms or solid form mixtures (e.g., Form B, Form C, Form X, and Mixture A) can also be obtained by subjecting or maintaining a Compound 1 solid form under physical conditions effective to convert Compound 1 as a first solid form into Compound 1 as a second solid form.
The present disclosure provides novel Compound 1 solid forms and mixtures thereof, pharmaceutical compositions thereof, methods of preparation thereof, and methods of use thereof. Compound 1 is the FASN inhibitor bioactive compound (4-(2-fluoro-4-(1-methyl-1H-benzo [d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone (Compound 1), can be prepared as one or more solid forms. The chemical structure of Compound 1 is shown below:
Compound 1 can occur in an amorphous solid form or in a crystalline solid form or in mixtures of solid forms. Crystalline solid forms of Compound 1 can exist in one or more unique solid forms, which can additionally comprise one or more equivalents of water or solvent (i.e., hydrates or solvates, respectively). Accordingly, in some embodiments, the present disclosure provides a crystalline solid form of Compound 1. Crystalline forms of Compound 1 disclosed herein have distinct characteristics (e.g., characteristic XRPD peaks disclosed herein).
Novel Compound 1 solid forms or solid form mixtures can be obtained by methods reported in the Examples (e.g., Example 2). Different methods of preparation can lead to different solid forms or solid form mixtures. For example, Compound 1 Form B can be obtained from a slurry comprising Compound 1 in ethanol at 50° C., as described in Example 2.
In some embodiments, certain solid forms or solid form mixtures of Compound 1 can be converted from one solid form to another solid form. For example, subjecting Compound 1 Mixture A and/or Form C to certain conditions yields at least Form B. Conditions suitable for converting Mixture A and/or Form C to Form B include conditions such as slurrying at room temperature, slurrying at 50° C., slurrying at 80° C., slurrying at reflux, and recrystallization.
Certain solid forms or solid form mixtures of Compound 1 can be prepared by forming a suspension (i.e., “slurrying”) comprising Compound 1 Mixture A and/or Form C and a solvent, and maintaining the suspension for a period of time sufficient to generate certain solid forms of Compound 1 (e.g., Form B). Exemplary solvents suitable to generate Form B include ethyl acetate (EtOAc), acetonitrile (ACN), heptane, isopropyl alcohol (IPA), and ethanol (EtOH). In some embodiments, a solvent is EtOAc. In some embodiments, a solvent is ACN. In some embodiments, a solvent is heptane. In some embodiments, a solvent is IPA. In some embodiments, a solvent is EtOH. In some embodiments, the suspension is maintained at room temperature. In some embodiments, the suspension is heated to a temperature between about 40° C. and 110° C. In some embodiments, the suspension is heated to a temperature of about 50° C. In some embodiments, the suspension is heated to a temperature of about 80° C. In some embodiments, the suspension is heated to a temperature of about 100° C. In some embodiments, the suspension is heated to reflux.
Certain solid forms or solid form mixtures of Compound 1 can be prepared by forming a suspension (i.e., “slurrying”) comprising Compound 1 Mixture A, Form C, and/or Form X and a solvent, and maintaining the suspension for a period of time sufficient to generate certain solid forms of Compound 1 (e.g., Form B). Exemplary solvents suitable to generate Form B include ethyl acetate (EtOAc), acetonitrile (ACN), heptane, isopropyl alcohol (IPA), and ethanol (EtOH). In some embodiments, a solvent is EtOAc. In some embodiments, a solvent is ACN. In some embodiments, a solvent is heptane. In some embodiments, a solvent is IPA. In some embodiments, a solvent is EtOH. In some embodiments, the suspension is maintained at room temperature. In some embodiments, the suspension is heated to a temperature between about 40° C. and 110° C. In some embodiments, the suspension is heated to a temperature of about 50° C. In some embodiments, the suspension is heated to a temperature of about 80° C. In some embodiments, the suspension is heated to a temperature of about 100° C. In some embodiments, the suspension is heated to reflux. In some embodiments, the disclosure relates to a solid form of Compound 1 that would be obtained by the foregoing process (or any embodiment thereof). In such embodiments, the solid form need not be prepared by such process, so long as the solid form is the same as the solid form that would be obtained by such process.
In some embodiments, certain solid forms of Compound 1 can be prepared by forming a salt of Compound 1, neutralizing said salt of Compound 1, and then allowing certain solid forms of Compound 1 (e.g., Form X) to precipitate from solution. For example, protonation of Compound 1 Form B with HCl in acetonitrile, followed by neutralization with NaOH (aq), and allowing precipitation at room temperature generates Compound 1 Form X.
In some embodiments, a solid form mixture of Compound 1 (e.g., Mixture A) is a mixture of two solid forms (e.g., Form B and another solid form). In some embodiments, a solid form mixture of Compound 1 (e.g., Mixture A) comprises two solid forms (e.g., Form B and another solid form).
The solid forms of Compound 1 disclosed herein include Compound 1 Form B, Form C, and Form X, as well as compositions comprising a solid form of Compound 1 comprising one or more of Form B, Form C, and Form X. The solid form mixtures of Compound 1 disclosed herein include Compound 1 in Mixture A, as well as compositions comprising a solid form mixture of Compound 1, comprising Mixture A. The solid forms and solid form mixtures of Compound 1 can be identified by various analytical techniques, such as XRPD and DSC.
A novel Compound 1 Mixture A can be identified by XRPD, having one or more characteristic diffractions at angles (2 theta±0.2) of 9.6, 10.1, 15.4, 19.6, and 22.3. A novel Compound 1 Mixture A can be identified by XRPD having characteristic diffractions at angles (2 theta±0.2) of 9.6, 10.1, 15.4, 19.6, and 22.3, and not having a diffraction at angle (2 theta±0.2) of 24.2. In some embodiments, Compound 1 Mixture A can be identified by XRPD, having one or more characteristic diffractions at angles (2 theta±0.2) of 9.6, 10.1, 15.4, 19.6, 21.0, and 22.3. In some embodiments, Compound 1 Mixture A can be identified by XRPD, having one or more characteristic diffractions at angles (2 theta±0.2) of 9.6, 10.1, 15.4, 19.6, and 22.3, corresponding to d-spacing (angstroms±0.2) of 9.3, 8.7, 5.7, 4.5, and 4.0, respectively.
In some embodiments, Compound 1 Mixture A is characterized by an XPRD having one or more peaks at substantially the same angles (2 theta±0.2) of:
In some embodiments, Compound 1 Mixture A is characterized by an XRPD having one or more peaks at substantially the same angles (2 theta±0.2), corresponding to d-spacing (angstroms±0.2L) of:
A novel Compound 1 Mixture A can be identified by DSC, having two endotherms at 226.2° C. and 229.1° C. In some embodiments, Compound 1 Mixture A can be identified (i) by DSC having two endotherms at 226.2° C. and 229.1° C.; and (ii) by XRPD having one or more characteristic diffractions at angles (2 theta±0.2) of 9.6, 10.1, 15.4, 19.6, and 22.3. In some embodiments, Compound 1 Mixture A can be identified (i) by DSC having two endotherms at 226.2° C. and 229.1° C.; (ii) by XRPD having one or more characteristic diffractions at angles (2 theta±0.2) of 9.6, 10.1, 15.4, 19.6, and 22.3; and (iii) by XRPD not having a characteristic diffraction at an angle (2 theta±0.2) of 24.2.
A novel Compound 1 Form B can be identified by XRPD, having one or more characteristic diffractions at angles (2 theta±0.2) of 9.6, 10.1, 15.4, 19.6, and 22.3. In some embodiments, Compound 1 Form B can be identified by XRPD, having one or more characteristic diffractions at angles (2 theta±0.2) of 9.6, 10.1, 15.4, 19.6, and 22.3, corresponding to d-spacing (angstroms±0.2) of 9.2, 8.7, 5.7, 4.5, and 4.0. In some embodiments, Compound 1 Form B can be identified by XRPD, (i) having one or more characteristic diffractions at angles (2 theta±0.2) of 9.6, 10.1, 15.4, 19.6, and 22.3, and (ii) not having a characteristic diffraction at an angle (2 theta±0.2) of 24.2. In some embodiments, Compound 1 Form B can be identified by XRPD, (i) having one or more characteristic diffractions at angles (2 theta±0.2) of 15.4, 19.6, and 22.3, and (ii) not having a characteristic diffraction at an angle (2 theta±0.2) of 24.2. In some embodiments, Compound 1 Form B can be identified by XRPD, (i) having one or more characteristic diffractions at angles (2 theta±0.2) of 9.6, 10.1, 15.4, 19.6, and 22.3, and (ii) not having one or more characteristic diffractions at angles (2 theta±0.2) of 7.2, 8.5, 14.9, 16.1, and 17.8. In some embodiments, Compound 1 Form B can be identified by XRPD, (i) having one or more characteristic diffractions at angles (2 theta±0.2) of 9.6, 10.1, 15.4, 19.6, and 22.3; (ii) not having a characteristic diffraction at an angle (2 theta±0.2) of 24.2; and (iii) not having one or more characteristic diffractions at angles (2 theta±0.2) of 7.2, 8.5, 14.9, 16.1, and 17.8.
In some embodiments, Compound 1 Form B is characterized by an XRPD having one or more peaks at substantially the same angles (2 theta±0.2) of:
In some embodiments, Compound 1 Form B is characterized by an XRPD having one or more peaks at substantially the same angles (2 theta±0.2), corresponding to d-spacing (angstroms±0.2) of:
A novel Compound 1 Form B can be identified by DSC, having one endotherm at 225.7° C. In some embodiments, Compound 1 Form B can be identified (i) by DSC having one endotherm at 225.7° C.; and (ii) by XRPD having one or more characteristic diffractions at angles (2 theta±0.2) of 9.6, 10.1, 15.4, 19.6, and 22.3. In some embodiments, Compound 1 Form B can be identified (i) by DSC having one endotherm at 225.7° C.; (ii) by XRPD having one or more characteristic diffractions at angles (2 theta±0.2) of 9.6, 10.1, 15.4, 19.6, and 22.3; and (iii) by XRPD not having one or more characteristic diffractions at angles (2 theta±0.2) of 7.2, 8.5, 14.9, 16.1, and 17.8. In some embodiments, Compound 1 Form B can be identified (i) by DSC having one endotherm at 225.7° C.; (ii) by XRPD having one or more characteristic diffractions at angles (2 theta±0.2) of 9.6, 10.1, 15.4, 19.6, and 22.3; and (iii) by XRPD not having a characteristic diffraction at angle (2 theta±0.2) of 24.2. In some embodiments, Compound 1 Form B can be identified (i) by DSC having one endotherm at 225.7° C.; (ii) by XRPD having one or more characteristic diffractions at angles (2 theta±0.2) of 9.6, 10.1, 15.4, 19.6, and 22.3; and (iii) by XRPD not having one or more characteristic diffractions at angles (2 theta±0.2) of 7.2, 8.5, 14.9, 16.1, 17.8, and 24.2. In some embodiments, Compound 1 Form B is substantially free of Form C and Form X.
A novel Compound 1 Form C can be identified by XRPD, having one or more characteristic diffractions at angles (2 theta±0.2) of 9.6, 15.4, 19.6, 22.3, and 26.6. In some embodiments, Compound 1 Form C can be identified by XRPD, having one or more characteristic diffractions at angles (2 theta±0.2) of 9.6, 15.4, 19.6, 22.3, 24.2, and 26.6. In some embodiments, Compound 1 Form C can be identified by XRPD, having one or more characteristic diffractions at angles (2 theta±0.2) of 9.6, 15.4, 19.6, 22.3, and 26.6, corresponding to d-spacing (angstroms±0.2) of 9.3, 5.7, 4.5, 4.0, and 3.3.
In some embodiments, Compound 1 Form C is characterized by an XRPD having one or more peaks at substantially the same angles (2 theta±0.2) of:
In some embodiments, Compound 1 Form C is characterized by an XRPD having one or more peaks at substantially the same angles (2 theta±0.2), corresponding to d-spacing (angstroms±0.2) of:
A novel Compound 1 Form C can be identified by DSC, having two endotherms at 101.1° C. and 224.0° C. In some embodiments, Compound 1 Form C can be identified (i) by DSC having two endotherms at 101.1° C. and 224.0° C.; and (ii) by XRPD having one or more characteristic diffractions at angles (2 theta±0.2) of 9.6, 15.4, 19.6, 22.3, and 26.6. In some embodiments, Compound 1 Form C is substantially free of Form B and Form X.
A novel Compound 1 Form X can be identified by XRPD, having one or more characteristic diffractions at angles (2 theta±0.2) of 7.2, 8.5, 14.9, 16.1, and 17.8. In some embodiments, Compound 1 Form X can be identified by XRPD, having one or more characteristic diffractions at angles (2 theta±0.2) of 7.2, 8.5, 14.9, 16.1, and 17.8, corresponding to d-spacing (angstroms±0.2) of 12.2, 10.4, 6.0, 5.5, and 5.0, respectively.
In some embodiments, Compound 1 Form X is characterized by an XRPD having one or more peaks at substantially the same angles (2 theta±0.2) of:
In some embodiments, Compound 1 Form X is characterized by an XRPD having one or more peaks at substantially the same angles (2 theta±0.2), corresponding to d-spacing (angstroms±0.2) of:
A novel Compound 1 Form X can be identified by DSC, having one endotherm at 232.9° C. In some embodiments, Compound 1 Form X can be identified (i) by DSC having one endotherm at 232.9° C.; and (ii) by XRPD having one or more characteristic diffractions at angles (2 theta±0.2) of 7.2, 8.5, 14.9, 16.1, and 17.8. In some embodiments, Compound 1 Form X is substantially free of Form B and Form C.
In some embodiments, the present disclosure provides a composition comprising amorphous and crystalline solid forms of Compound 1. In some embodiments, the composition comprises crystalline Compound 1 and amorphous Compound 1, wherein the amorphous Compound 1 is present in an amount selected from the following ranges: 90-99%, 80-89%, 70-79%, 60-69%, 50-59%, 40-49%, 30-39%, 20-29%, 10-19%, 1-9% and 0-0.99%.
In some embodiments, a crystalline form of Compound 1 is anhydrous. In some embodiments, an anhydrous crystalline form of Compound 1 is selected from Mixture A, Form B, and Form X. In some embodiments, an anhydrous crystalline form of Compound 1 is Mixture A. In some embodiments, an anhydrous crystalline form of Compound 1 is Form B. In some embodiments, an anhydrous crystalline form of Compound 1 is Form X. In some embodiments, an anhydrous crystalline form of Compound 1 is a mixture of Form B and another solid form (e.g., Mixture A).
In some embodiments, a crystalline form of Compound 1 is a hydrate. In some embodiments, a hydrate crystalline form of Compound 1 is Form C.
A pharmaceutical composition can comprise and/or be obtained from the solid form of Compound 1, designated as Form B, that produces an XRPD pattern having one or more diffractions at angles (2 theta±0.2) of 9.6, 10.1, 15.4, 19.6, and 22.3. In some embodiments, the pharmaceutical composition can comprise and/or be obtained from Compound 1 Form B, which can be identified by an XRPD pattern having one or more diffractions at angles (2 theta±0.2) of 9.6, 10.1, 15.4, 19.6, and 22.3, corresponding to d-spacing (angstroms±0.2) of 9.2, 8.7, 5.7, 4.5, and 4.0. In some embodiments, the pharmaceutical composition can comprise and/or be obtained from Compound 1 Form B, which can be identified by XRPD, (i) having one or more characteristic diffractions at angles (2 theta±0.2) of 9.6, 10.1, 15.4, 19.6, and 22.3; and (ii) not having a characteristic diffraction at an angle (2 theta±0.2) of 24.2. In some embodiments, the pharmaceutical composition can comprise and/or be obtained from Compound 1 Form B, which can be identified by XRPD, (i) having one or more characteristic diffractions at angles (2 theta±0.2) of 15.4, 19.6, and 22.3; and (ii) not having a characteristic diffraction at an angle (2 theta±0.2) of 24.2. In some embodiments, the pharmaceutical composition can comprise and/or be obtained from Compound 1 Form B, which can be identified by XRPD (i) having one or more characteristic diffractions at angles (2 theta±0.2) of 9.6, 10.1, 15.4, 19.6, and 22.3, and (ii) not having one or more characteristic diffractions at angles (2 theta±0.2) of 7.2, 8.5, 14.9, 16.1, and 17.8. In some embodiments, the pharmaceutical composition can comprise and/or be obtained from Compound 1 Form B, which can be identified by XRPD, (i) having one or more characteristic diffractions at angles (2 theta±0.2) of 9.6, 10.1, 15.4, 19.6, and 22.3; (ii) not having a characteristic diffraction at an angle (2 theta±0.2) of 24.2; and (iii) not having one or more characteristic diffractions at angles (2 theta±0.2) of 7.2, 8.5, 14.9, 16.1, and 17.8. In some embodiments, the pharmaceutical composition can comprise any one of the solid forms of Compound 1 described herein. In some embodiments, the pharmaceutical composition is substantially free of Compound 1 Form X. In some embodiments, the pharmaceutical composition can comprise and/or be obtained from a solid form consisting of Compound 1 Form B.
A pharmaceutical composition can comprise and/or be obtained from the solid form of Compound 1, designated as Form B, that can be identified by DSC, having one endotherm at 225.7° C. In some embodiments, the pharmaceutical composition can comprise and/or be obtained from Compound 1 Form B, which can be identified (i) by DSC having one endotherm at 225.7° C.; and (ii) by XRPD having one or more characteristic diffractions at angles (2 theta±0.2) of 9.6, 10.1, 15.4, 19.6, and 22.3. In some embodiments, the pharmaceutical composition can comprise and/or be obtained from Compound 1 Form B, which can be identified (i) by DSC having one endotherm at 225.7° C.; (ii) by XRPD having one or more characteristic diffractions at angles (2 theta±0.2) of 9.6, 10.1, 15.4, 19.6, and 22.3; and (iii) by XRPD not having one or more characteristic diffractions at angles (2 theta±0.2) of 7.2, 8.5, 14.9, 16.1, 17.8, and 24.2.
Pharmaceutical compositions reported herein can be combined with a pharmaceutically acceptable carrier or excipient. In some embodiments, pharmaceutical compositions reported herein can be provided in a unit dosage form container (e.g., in a vial or bag or the like). In some embodiments, pharmaceutical compositions reported herein can be provided in an oral dosage form. In some embodiments, an oral dosage form is a capsule. In some embodiments, an oral dosage form is a tablet.
In some embodiments, the present disclosure provides methods of inhibiting FASN, comprising administering a solid form of Compound 1 to a subject. In some embodiments, the present disclosure provides methods of treating a disease, disorder, or condition responsive to inhibition of FASN, comprising administering a solid form of Compound 1 to a subject in need thereof. In some embodiments, the disease, disorder, or condition is non-alcoholic steatohepatitis (NASH).
In some embodiments, the present disclosure relates to:
1. Crystalline (4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl) methanone.
2. A solid form of Compound 1:
3. The solid form of embodiment 2, wherein the solid form is characterized by an XRPD pattern having diffractions at angles (2 theta±0.2) of 9.6, 10.1, 15.4, 19.6, and 22.3.
4. The solid form of embodiment 3, wherein the solid form is characterized by an XRPD pattern having diffractions at angles (2 theta±0.2) of 9.6, 10.1, 15.4, 19.6, and 22.3, and not having one or more diffractions at angles (2 theta±0.2) of 7.2, 8.5, 14.9, 16.1, and 17.8.
5. The solid form of embodiment 3 or 4, wherein the solid form is characterized by an XRPD pattern having diffractions at angles (2 theta±0.2) of 9.6, 10.1, 15.4, 19.6, and 22.3 and not having a diffraction at angle (2 theta±0.2) of 24.2.
6. The solid form of any one of the preceding embodiments, wherein the solid form is characterized by an XRPD pattern having diffractions at angles (2 theta±0.2) of 9.6, 10.1, 15.4, 19.6, and 22.3, corresponding to d-spacing (ű0.2) of 9.2, 8.7, 5.7, 4.5, and 4.0, respectively.
7. The solid form of any one of the preceding embodiments, wherein the solid form is characterized by an XRPD pattern having diffractions at angles (2 theta±0.2) of:
8. The solid form of any one of the preceding embodiments, wherein the solid form is characterized by an XRPD pattern having diffractions at angles (2 theta±0.2) corresponding to d-spacing (ű0.2) of:
9. The solid form of any one of the preceding embodiments, wherein the solid form is characterized by an XRPD pattern expressed in terms of angles (2 theta±0.2) and obtained with a diffractometer according to one or more parameters from Table 1, and wherein the X-ray powder diffraction pattern comprises diffractions at angles (2 theta±0.2) of 9.6, 10.1, 15.4, 19.6, and 22.3.
10. The solid form of any one of the preceding embodiments, wherein the solid form is characterized by a DSC endotherm having an endotherm at about 226° C.
11. The solid form of any one of the preceding embodiments, wherein the solid form is characterized by a DSC endotherm expressed in terms of degrees and obtained with a calorimeter according to one or more parameters from Table 3, wherein the DSC endotherm is at about 226° C.
12. The solid form of any one of the preceding embodiments, wherein the solid form is characterized by a TGA with a weight loss of about 0.5% between 21° C. and 100° C.
13. The solid form of any one of the preceding embodiments, wherein the solid form is characterized by a DVS of about 0.5% water by weight below 95% relative humidity.
14. The solid form of any one of the preceding embodiments, wherein the solid form is Solid Form B.
15. The solid form of embodiment 2, wherein the solid form is characterized by an XRPD pattern having diffractions at angles (2 theta±0.2) of 9.6, 15.4, 19.6, 22.3, and 26.6.
16. The solid form of embodiment 15, wherein the solid form is characterized by an XRPD pattern having diffractions at angles (2 theta±0.2) of 9.6, 15.4, 19.6, 22.3, and 26.6, corresponding to d-spacing (ű0.2) of 9.3, 5.7, 4.5, 4.0, and 3.3, respectively.
17. The solid form of embodiment 15 or 16, wherein the solid form is characterized by an XRPD pattern having diffractions at angles (2 theta±0.2) of:
18. The solid form of any one of embodiments 15-17, wherein the solid form is characterized by an XRPD pattern having diffractions at angles (2 theta±0.2) corresponding to d-spacing (ű0.2) of:
19. The solid form of any one of embodiments 15-18, wherein the solid form is characterized by an X-ray powder diffraction pattern expressed in terms of angles (2 theta±0.2) and obtained with a diffractometer according to one or more parameters from Table 1, and wherein the X-ray powder diffraction pattern comprises diffractions at angles (2 theta±0.2) of 9.6, 15.4, 19.6, 22.3, and 26.6.
20. The solid form of any one of embodiments 15-19, wherein the solid form is characterized by a DSC endotherm having two endotherms at about 101.1° C. and about 224.0° C.
21. The solid form of any one of embodiments 15-20, wherein the solid form is characterized by a DSC endotherm expressed in terms of degrees and obtained with a calorimeter according to one or more parameters from Table 3, wherein the DSC endotherm is at about 101.1° C. and about 224.0° C.
22. The solid form of any one embodiments 15-21, wherein the solid form is characterized by a TGA with a weight loss of about 5.77% between 21° C. and 100° C.
23. The solid form of any one of embodiments 15-22, wherein the solid form is Solid Form C.
24. The solid form of embodiment 2, wherein the solid form is characterized by an XRPD pattern having diffractions at angles (2 theta±0.2) of 7.2, 8.5, 14.9, 16.1, and 17.8.
25. The solid form of embodiment 24, wherein the solid form is characterized by an XRPD pattern having diffractions at angles (2 theta±0.2) of 7.2, 8.5, 14.9, 16.1, and 17.8, corresponding to d-spacing (ű0.2) of 12.2, 10.4, 6.0, 5.5, and 5.0, respectively.
26. The solid form of embodiment 24 or 25, wherein the solid form is characterized by an XRPD pattern having diffractions at angles (2 theta±0.2) of:
27. The solid form of any one of embodiments 24-26, wherein the solid form is characterized by an XRPD pattern having diffractions at angles (2 theta±0.2) corresponding to d-spacing (ű0.2) of:
28. The solid form of any one of embodiments 24-27, wherein the solid form is characterized by an XRPD pattern expressed in terms of angles (2 theta±0.2) and obtained with a diffractometer according to one or more parameters from Table 1, and wherein the X-ray powder diffraction pattern comprises diffractions at angles (2 theta±0.2) of 7.2, 8.5, 14.9, 16.1, and 17.8.
29. The solid form of any one of embodiments 24-28, wherein the solid form is characterized by a DSC endotherm having an endotherm at about 232.9° C.
30. The solid form of any one embodiments 24-29, wherein the solid form is characterized by a DSC endotherm expressed in terms of degrees and obtained with a calorimeter according to one or more parameters from Table 3, wherein the DSC endotherm is at about 232.9° C.
31. The solid form of any one embodiments 24-30, wherein the solid form is characterized by a TGA with a weight loss of about 0.47% between 21° C. and 150° C.
32. The solid form of any one of embodiments 24-31, wherein the solid form is Solid Form X.
33. A composition comprising a mixture of solid forms of Compound 1:
34. The composition of embodiment 33, wherein the composition is characterized by an XRPD pattern having diffractions at angles (2 theta±0.2) of 9.6, 10.1, 15.4, 19.6, and 22.3.
35. The composition of embodiment 33 or 34, wherein the solid form mixture is characterized by an XRPD pattern having diffractions at angles (2 theta±0.2) of 9.6, 10.1, 15.4, 19.6, and 22.3, corresponding to d-spacing (ű0.2) of 9.3, 8.7, 5.7, 4.5, and 4.0, respectively.
36. The composition of any one of embodiments 33-35, wherein the solid form mixture is characterized by an XRPD pattern having diffractions at angles (2 theta±0.2) corresponding to d-spacing (ű0.2) of:
37. The composition of any one of embodiments 33-36, wherein the solid form is characterized by an XRPD pattern having diffractions at angles (2 theta±0.2) corresponding to d-spacing (ű0.2) of:
38. The solid form of any one of embodiments 33-37, wherein the solid form is characterized by an XRPD pattern expressed in terms of angles (2 theta±0.2) and obtained with a diffractometer according to one or more parameters from Table 1, and wherein the X-ray powder diffraction pattern comprises diffractions at angles (2 theta±0.2) of 9.6, 10.1, 15.4, 19.6, and 22.3.
39. The composition of any one of embodiments 33-38, wherein the solid form mixture is characterized by a DSC endotherm having two endotherms at about 226.2° C. and about 229.1° C.
40. The solid form of any one embodiments 33-39, wherein the solid form is characterized by a DSC endotherm expressed in terms of degrees and obtained with a calorimeter according to one or more parameters from Table 3, wherein the DSC endotherm is at about 226.2° C. and about 229.1° C.
41. The composition of any one embodiments 33-40, wherein the solid form mixture is characterized by a TGA with a weight loss of about 1.73% between 21° C. and 150° C.
42. The composition of any one of embodiments 33-41, wherein the solid form mixture is Solid Form Mixture A.
43. A pharmaceutical composition comprising a solid form of Compound 1:
and a pharmaceutically acceptable carrier.
44. The pharmaceutical composition of embodiment 43, wherein the solid form is characterized by an XRPD pattern having diffractions at angles (2 theta±0.2) of 9.6, 10.1, 15.4, 19.6, and 22.3.
45. The pharmaceutical composition of embodiment 43 or 44, wherein the solid form is characterized by an XRPD pattern having diffractions at angles (2 theta±0.2) of 9.6, 10.1, 15.4, 19.6, and 22.3, and not having one or more diffractions at angles (2 theta±0.2) of 7.2, 8.5, 14.9, 16.1, and 17.8.
46. The pharmaceutical composition of any one of embodiments 43-45, wherein the solid form is characterized by an XRPD pattern having diffractions at angles (2 theta±0.2) of 9.6, 10.1, 15.4, 19.6, and 22.3 and not having a diffraction at angle (2 theta±0.2) of 24.2.
47. The pharmaceutical composition of any one of embodiments 43-46, wherein the solid form is characterized by an XRPD pattern having diffractions at angles (2 theta±0.2) of 9.6, 10.1, 15.4, 19.6, and 22.3, corresponding to d-spacing (ű0.2) of 9.2, 8.7, 5.7, 4.5, and 4.0, respectively.
48. The pharmaceutical composition of any one of embodiments 43-47, wherein the solid form is characterized by an XRPD pattern having diffractions at angles (2 theta±0.2) of:
49. The pharmaceutical composition of any one of embodiments 43-48, wherein the solid form is characterized by an XRPD pattern having diffractions at angles (2 theta±0.2) corresponding to d-spacing (ű0.2) of:
50. The solid form of any one of embodiments 43-49, wherein the solid form is characterized by an XRPD pattern expressed in terms of angles (2 theta±0.2) and obtained with a diffractometer according to one or more parameters from Table 1, and wherein the X-ray powder diffraction pattern comprises diffractions at angles (2 theta±0.2) of 9.6, 10.1, 15.4, 19.6, and 22.3.
51. The pharmaceutical composition of any one of embodiments 43-50, wherein the solid form is characterized by a DSC endotherm having an endotherm at about 226° C.
52. The solid form of any one of embodiments 43-51, wherein the solid form is characterized by a DSC endotherm expressed in terms of degrees and obtained with a calorimeter according to one or more parameters from Table 3, wherein the DSC endotherm is at about 226° C.
53. The pharmaceutical composition of any one of embodiments 43-52, wherein the solid form is characterized by a TGA with a weight loss of about 0.5% between 21° C. and 100° C.
54. The pharmaceutical composition of any one of embodiments 43-53, wherein the solid form is characterized by a DVS of about 0.5% water by weight below 95% relative humidity.
55. The pharmaceutical composition of any one of embodiments 43-54, wherein the solid form is Solid Form B.
56. A process for preparing Solid Form B of (4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl) benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone (Compound 1) comprising suspending at least one of Mixture A, Form C, and Form X in a solvent to provide a slurry, and maintaining the slurry for a period of time under conditions effective to generate Solid Form B of Compound 1.
57. The process of embodiment 56, wherein the solvent is selected from the group consisting of ethyl acetate (EtOAc), acetonitrile (ACN), heptane, isopropyl alcohol (IPA), and ethanol (EtOH).
58. The process of embodiment 56 or 57, wherein the slurry is heated to a temperature from about 50° C. to about 100° C. after suspension in the solvent.
59. The process of any one of embodiments 56-58, further comprising isolating Solid Form B of Compound 1 from the slurry.
60. A solid form obtained by a process described herein.
61. The solid form of embodiment 60, wherein the solid form is Form B.
62. The solid form of embodiment 60, wherein the solid form is Form C.
63. The solid form of embodiment 60, wherein the solid form is Form X.
64. A composition obtained by a process described herein.
65. The composition of embodiment 64, wherein the composition is Solid Form Mixture A.
In some embodiments, the present disclosure relates to:
1. Crystalline (4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1- hydroxycyclopropyl)methanone.
2. A solid form of Compound 1:
3. The solid form of embodiment 2, wherein the solid form is characterized by an XRPD pattern having diffractions at angles (2 theta±0.2) of 9.6, 10.1, 15.4, 19.6, and 22.3.
4. The solid form of embodiment 3, wherein the solid form is characterized by an XRPD pattern having diffractions at angles (2 theta±0.2) of 9.6, 10.1, 15.4, 19.6, and 22.3 and not having a diffraction at angle (2 theta±0.2) of 24.2.
5. The solid form of embodiment 2, wherein the solid form is characterized by an XRPD pattern having diffractions at angles (2 theta±0.2) of 15.4, 19.6, and 22.3 and not having a diffraction at angle (2 theta±0.2) of 24.2.
6. The solid form of any one of the preceding embodiments, wherein the solid form is characterized by a DSC endotherm having an endotherm at about 226° C.
7. The solid form of any one of the preceding embodiments, wherein the solid form is characterized by a TGA with a weight loss of about 0.5% between 21° C. and 100° C.
8. The solid form of any one of the preceding embodiments, wherein the solid form is characterized by a DVS of about 0.5% water by weight below 95% relative humidity.
9. The solid form of any one of the preceding embodiments, wherein the solid form is Solid Form B.
10. The solid form of embodiment 2, wherein the solid form is characterized by an XRPD pattern having diffractions at angles (2 theta±0.2) of 9.6, 15.4, 19.6, 22.3, and 26.6.
11. The solid form of embodiment 2, wherein the solid form is characterized by an XRPD pattern having diffractions at angles (2 theta±0.2) of 9.6, 15.4, 19.6, 22.3, 24.2, and 26.6.
12. The solid form of embodiment 2, wherein the solid form is characterized by an XRPD pattern having diffractions at angles (2 theta±0.2) of 7.2, 8.5, 14.9, 16.1, and 17.8.
13. A composition comprising a mixture of solid forms of Compound 1:
14. The composition of embodiment 13, wherein the composition is characterized by an XRPD pattern having diffractions at angles (2 theta±0.2) of 9.6, 10.1, 15.4, 19.6, and 22.3.
15. The composition of embodiment 13, wherein the composition is characterized by an XRPD pattern having diffractions at angles (2 theta±0.2) of 9.6, 10.1, 15.4, 19.6, 21.0, and 22.3.
16. A pharmaceutical composition comprising a solid form of Compound 1:
and a pharmaceutically acceptable carrier.
17. The pharmaceutical composition of embodiment 16, wherein the solid form of Compound 1 is the solid form of any one of embodiments 1-12.
18. The pharmaceutical composition of embodiment 16, wherein the solid form is characterized by an XRPD pattern having diffractions at angles (2 theta±0.2) of 9.6, 10.1, 15.4, 19.6, and 22.3.
19. The pharmaceutical composition of any one of embodiments 16-18, wherein the solid form is characterized by an XRPD pattern having diffractions at angles (2 theta±0.2) of 9.6, 10.1, 15.4, 19.6, and 22.3 and not having a diffraction at angle (2 theta±0.2) of 24.2.
20. The pharmaceutical composition of embodiment 16, wherein the solid form is characterized by an XRPD pattern having diffractions at angles (2 theta±0.2) of 15.4, 19.6, and 22.3 and not having a diffraction at angle (2 theta±0.2) of 24.2.
21. The pharmaceutical composition of any one of embodiments 16-20, wherein the solid form is Solid Form B.
22. The pharmaceutical composition of any one of embodiments 16-21, wherein the pharmaceutical composition is substantially free of Solid Form X.
23. The pharmaceutical composition of embodiment 16, wherein the solid form consists of Solid Form B.
24. A process for preparing Solid Form B of (4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl) (1-hydroxycyclopropyl)methanone (Compound 1) comprising suspending at least one of Mixture A, Form C, and Form X in a solvent to provide a slurry, and maintaining the slurry for a period of time under conditions effective to generate Solid Form B of Compound 1.
25. The process of embodiment 24, wherein the solvent is selected from the group consisting of ethyl acetate (EtOAc), acetonitrile (ACN), heptane, isopropyl alcohol (IPA), and ethanol (EtOH).
26. The process of embodiment 24 or 25, wherein the slurry is heated to a temperature from about 50° C. to about 100° C. after suspension in the solvent.
27. The process of any one of embodiments 24-26, further comprising isolating Solid Form B of Compound 1 from the slurry.
28. A solid form of Compound 1:
wherein the solid form is the form that would be obtained by a process comprising:
suspending at least one of Mixture A, Form C, and Form X of Compound 1 in a solvent selected from a group consisting of ethyl acetate (EtOAc), acetonitrile (ACN), heptane, isopropyl alcohol (IPA), and ethanol (EtOH) to provide a slurry; and
maintaining the slurry for a period of at least 5 hours to afford the solid form of Compound 1.
29. The solid form of embodiment 28, wherein the slurry is heated to a temperature from about 50° C. to about 100° C. after suspension in the solvent.
30. The solid form of embodiment 28 or 29, further comprising isolating the solid form of Compound 1 from the slurry.
Instrumentation and Methods
Unless otherwise indicated, the following instrumentation and methods were used in the working examples described herein.
X-ray Powder Diffraction (XRPD)
High resolution XRPD experiments were performed with Panalytical X′Pert3 Powder XRPD on a Si zero-background holder. The 2θposition was calibrated against Panalytical 640 Si powder standard. Details of the XRPD method are listed in Table 1 below:
Peaks are reported as diffraction angles at 2 theta, with d-spacing measured in angstroms.
Thermal Analysis
TGA experiments were performed on TA Q500 TGA from TA Instruments. Samples were heated at 10° C./min from about 20° C. to about 350° C. using dry nitrogen to purge the system. The details of the method are provided in Table 2, below:
DSC experiments were performed on TA Q2000 DSC from TA Instruments. Samples were heated at 10° C. to about 350° C. using dry nitrogen to purge the system. The details of the method are providing in Table 3, below:
Dynamic Vapor Sorption
DVS was obtained using a Surface Measurement System (SMS) DVS Intrinsic. The details of the method are providing in Table 4, below:
High Pressure Liquid Chromatography
High Pressure Liquid Chromatography (HPLC) data was obtained according to Table 5, below:
The synthesis of (4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl) benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone (“Compound 1”) was previously reported in PCT Application Publication No. WO 2014/164749. Compound 1 may be prepared as shown below:
Step 1. tert-butyl 4-(4-bromo-2-fluorobenzoyl)piperazine-1-carboxylate
A 5 L multi-neck round bottom flask fitted with nitrogen inlet and overhead stirring was charged with 4-bromo-2-fluorobenzoyl chloride (100 g, 421 mmol), tert-butyl piperazine-1-carboxylate (78 g, 421 mmol), dimethylformamide (DMF) (750 mL), and diisopropylethylamine ((i-Pr)2NEt; DIEA) (221 mL, 1263 mmol). The mixture was stirred at room temperature (rt) and monitored by liquid chromatography/mass spectrometry (LC/MS) for completion. Upon completion (ca. 2 hours) 0.2 M HCl (300 mL) was slowly added while maintaining internal temperature below 35° C. The heterogeneous mixture was stirred at rt for 3 hours, and then the solids were isolated by filtration. The reaction vessel and solids were washed with water (300 mL) and the solids were dried under house vacuum (17 torr) to afford tert-butyl 4-(4-bromo-2-fluorobenzoyl) piperazine-1-carboxylate (151 g, 93% yield) as an off white solid.
Step 2. (4-(4-(tert-butoxycarbonyl)piperazine-1-carbonyl)-3-fluorophenyl)boronic acid
A 5 L multi-neck round bottom flask fitted with nitrogen inlet, overhead stirring, thermocouple and condenser was charged with tert-butyl 4-(4-bromo-2-fluorobenzoyl)piperazine-1-carboxylate (125 g, 323 mmol), potassium acetate (79 g, 807 mmol), 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (102 g, 403 mmol), 2-methyl tetrahydrofuran (1250 mL). The mixture was sparged with nitrogen and then PdCl2(dppf) was added (2.362 g, 3.23 mmol). The mixture was heated to 75° C. and monitored for completion by LC/MS. Upon completion (about 24 hours) the mixture was cooled to rt and diluted with water (1250 mL). The bi-phasic mixture was filtered through celite, and the reaction vessel and celite were washed with fresh 2-methyltetrahydrofuran (250 mL). The phases were separated and the organic phase was washed with water (1250 mL). The organic phase was diluted with 1M NaOH (1250 mL) and the phases separated. The aqueous (product containing) phase was diluted with fresh 2-methyltetrahydrofuran (1400 mL), and the pH was adjusted to 1.0 with 6 M HCl. The phases were separated, and the organic (product containing) phase was filtered through celite and added to a 5 L multi-neck round bottom flask fitted with nitrogen inlet and overhead stirring, containing water (1400 mL) and sodium periodate (110 g, 516 mmol). The mixture was stirred for 1 hour, followed by the addition of 1 M HCl (980 ml). The mixture was stirred at rt and monitored for completion by LC/MS. Upon completion (about 18 hours) the phases were separated, and the organic phase was washed with 20 wt % aqueous Na2S2O3 (500 mL), water (500 mL), and brine (500 mL). The organic phase was dried with magnesium sulfate, filtered, and the solids washed with fresh 2-methyltetrahydrofuran (200 mL). The filtrate was concentrated to dryness under reduced pressure to afford (4-(4-(tert-butoxycarbonyl)piperazine-1-carbonyl)-3-fluorophenyl)boronic acid (100.22 g, 88% yield) as a tan solid.
Step 3. tert-butyl 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazine-1-carboxylate
Into a 100-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed a solution of (4-(4-(tert-butoxycarbonyl)piperazine-1-carbonyl)-3L-fluorophenyl) boronic acid (620 mg, 1.42 mmol, 1.00 equiv), toluene (10 mL), 5-bromo-1-methyl-1H-1,3-benzodiazole (300 mg, 1.42 mmol, 1.00 equiv), Pd(PPh3)4 (198 mg, 0.17 mmol, 0.12 equiv), sodium carbonate (2 M, 5 mL), and ethanol (1.4 mL). The resulting mixture was stirred overnight at 95° C. After cooling to room temperature, the mixture was diluted with 20 mL H2O, extracted with 3×30 mL of ethyl acetate. All the organic layers were combined, dried over anhydrous sodium sulfate, and concentrated under vacuum. The residue was loaded onto a silica gel column with dichloromethane/methanol (95:5). The collected fractions were combined and concentrated under vacuum. This resulted in 600 mg (96%) of tert-butyl 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl) benzoyl)piperazine-1-carboxylate as a yellow solid. LC-MS (ES, m/z): 439 [M+H]+.
Step 4. (2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)phenyl)(piperazin-1-yl)methanone (hydrochloride salt)
Into a 100-mL round-bottom flask, was placed a solution of tert-butyl 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl) benzoyl)piperazine-1-carboxylate (600 mg, 1.37 mmol, 1.00 equiv) in ethyl acetate (EA)/THF(1:1, 20 mL). Hydrogen chloride gas was then bubbled into the reaction mixture. The solution was stirred for 30 min at room temperature. The solids were collected by filtration and dried under reduced pressure. This resulted in 460 mg (100%) of (2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl) phenyl)(piperazin-1-yl)methanone (hydrochloride salt) as an off-white solid. LC-MS (ES, m/z): 339 [M+H]+.
Step 5. (4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone
Into a 100-mL round-bottom flask, was placed a solution of (2-fluoro-4L-(1-methyl-1H-benzo[d]imidazol-5-yl) phenyl)(piperazin-1-yl)methanone (hydrochloride salt) (398 mg, 1.18 mmol, 1.00 equiv) in N,N-dimethylformamide (20 mL), 1-hydroxycyclopropane-1-carboxylic acid (120 mg, 1.18 mmol, 1.00 equiv), HBTU (669 mg, 1.76 mmol, 1.50 equiv), and DIEA (608 mg, 4.70 mmol, 4.00 equiv). The resulting mixture was stirred overnight at room temperature. The solution was diluted with 30 mL of EA, washed with 3>30 mL H2O. The organic phase was dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was loaded onto a silica gel column with EA/petroleum ether (0:100-100:0). The collected fractions were combined and concentrated under vacuum to dryness. This resulted in 152.8 mg (31%) of (4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl) benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone as a white solid. LC-MS: (ES, m/z): 423[M+H]+. 1H-NMR: (CD3OD, 300 MHz): δ8.20 (s, 1H), 7.96 (s, 1H), 7.68-7.63 (m, 3H), 7.59-7.50 (m, 2H), 3.95-3.72 (m, 9H), 3.50 (s, 2H), 1.10-1.06 (m, 2H), 0.93L-0.89 (m, 2H).
Compound 1 Mixture A was prepared by replacing step 5 of Example 1 with step 6:
Step 6: (4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone
To a solution of 1-hydroxycyclopropane-1-carboxylic acid (30 g, 294 mmol) in DMF (900 mL) was added HBTU (36 g, 95.6 mmol), 5-[3-fluoro-4-[(piperazin-1-yl)carbonyl]phenyl]-1-methyl-1H-1, 3-benzodiazole hydrochloride (8.6 g, 22.9 mmol), and DIEA (52.8 mL, 319 mmol). The resulting solution was stirred for 18 hours at 20° C. The reaction mixture was poured into water (4 L) and then extracted with DCM (4×1.5 L). The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting crude product was purified by reversed phase chromatography (5% to 35% MeCN/water (containing 0.1% NH4HCO3) over 30 min). The fractions were collected and lyophilized. The product was further purified by recrystallization with MeOH/water (1:2) and dried under vacuum to afford 1-[(4-[[2-fluoro-4-(1-methyl-1H-1,3-benzodiazol-5-yl)phenyl]carbonyl]piperazin-1-yl) carbonyl]cyclopropan-1-ol as a white solid (11.46 g, 33.9%).The XRPD pattern of the crystalline Compound 1 Mixture A is depicted in
As shown by TGA and DSC curves in
Without wishing to be bound by any particular theory, Applicant has observed that Mixture A is an apparent mixture of two anhydrous forms: Form B and another solid form, as is apparent from the extra reflections in XRPD (
Form B
Compound 1 Form B was prepared by one of the following procedures.
Procedure 1: Mixture A (0.10 g) was recrystallized from ACN-water (ca. 9:1, 10 volumes) to give Form B in 72% recovery.
Procedure 2: Form C (0.25 g) was slurried in heptane (40 volumes) at 100° C. for 7 hours, then cooled to room temperature and filtered to give Form B in 80% recovery, 98.95% purity.
Procedure 3: Form C (0.25 g) was slurried in IPA (40 volumes) at 80° C. for 7 hours, then cooled to room temperature and filtered to give Form B in 60% recovery, 99.02% purity.
Procedure 4: Form C (21 g) was slurried in heptane (10 volumes) at 105° C. for 5 hours, then cooled to room temperature, and filtered to give Form B in 91% recovery, 98.79% purity.
Procedure 5: Form C (30 g) was combined in IPA (15 volumes) and heated to reflux. IPA (7.5 volumes) was then distilled off. The resulting suspension was cooled to room temperature, filtered and dried at 50° C. and 80° C. to give 91% recovery, 99.27% purity.
Procedure 6: Form C (1.0 g) was dissolved in N-methyl-2-pyrrolidone (NMP) (9 volumes) at 50° C. The solution was cooled to room temperature and filtered. IPA (18 volumes) was added to the filtrate, then Form B seed crystals were added. The slurry was stirred at room temperature, filtered and dried to give 73% recovery, 99.48% purity.
Procedure 7: Form C (25 g) was slurried in ethanol (15 volumes) at 50° C. for 8 hours. The slurry was cooled to rt and filtered to give 99.51% purity.
Procedure 8: The final step of Example 1 was replaced with step 6:
Step 6: (4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone
A 250-mL round-bottomed flask was charged with (2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)phenyl) (piperazin-1-yl)methanone (hydrochloride salt) (10. 36 g, 1.00 equiv), HOBt (861 mg, 1.30 equiv), and EtOH (40 mL). With moderate agitation, the suspension was charged with 3 M NaOH (aq) (19.0 mL, 2.35 equiv), and the reaction mixture was agitated at room temperature for 10 minutes. The reaction mixture was filter using a Buchner funnel to give a first solution. A separate 100-mL round-bottomed flask was charged with EDC·HCl (5.59 g, 1.2 equiv) and 25 mL EtOH. The resulting mixture was agitated at room temperature for 10 minutes, and then filtered using a Buchner funnel to give a second solution. To the first solution was added the second solution over the course of an hour. The reaction mixture was agitated at room temperature for about 7 hours. The reaction mixture was then added to water (250 mL) in portions over the course of an hour, and the resulting mixture was agitated for about 3 hours. The reaction mixture was filtered using a Buchner funnel and washed with water (100 mL) to give (4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl) benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone in about 90% yield.
The XRPD pattern of the crystalline Compound 1 Form B is depicted in
As shown by TGA and DSC curves in
DVS analysis was also conducted for Form B. As shown in
A study was conducted on a sample of Compound 1 (Form B) where samples were exposed (open) to a range of elevated temperatures (50-80° C.) and controlled relative humidity (RH) (0-80% RH). Compound 1 exhibits good chemical stability, and the estimated shelf life is greater than 5 years at 25° C./60% RH.
Form C
Compound 1 Form C was prepared by replacing step 5 of Example 1 with either step 7a or step 7b:
Step 7a: (4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone
To a 2-L, three-necked, round-bottomed flask fitted with a nitrogen inlet, and overhead stirring was added (2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)phenyl)(piperazin-1-yl)methanone dihydrochloride (139.21 g, 338 mmol), 1-hydroxycyclopropanecarboxylic acid (44.9 g, 440 mmol), 1-hydroxybenzotriazole hydrate (10.37 g, 67.7 mmol), N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (84 g, 440 mmol), dimethyl sulfoxide (DMSO) (700 mL), and 4-methylmorpholine (167 mL, 1523 mmol). The mixture stirred at rt and monitored for completion by LC/MS. Upon reaction completion (ca. 18 hours) the mixture was added to a 5-L, three-necked, round-bottomed flask fitted with a nitrogen inlet and overhead stirring containing water (2800 mL). The mixture was granulated for 24 hours and then filtered. The isolated solids were then stirred in water (1200 mL) at rt for 4 hours, filtered, and washed with water (300 mL). The solids were dried on filter under a nitrogen atmosphere followed by house vacuum (ca. 17 torr) to afford (4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl) benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone (118.7 g, 83% yield) as a white solid.
Step 7b: (4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl) benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone
To a 50-mL, round-bottomed flask fitted with a nitrogen inlet and magnetic stir bar was added (2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)phenyl)(piperazin-1-yl)methanone dihydrochloride (3.0 g, 7.29 mmol), 1-hydroxycyclopropane-1-carboxylic acid (0.968 g, 9.48 mmol), 1-hydroxybenzotriazole hydrate (0.223 g, 1.459 mmol), N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (1.818 g, 9.48 mmol), N-Methyl-2-pyrrolidinone (NMP) (15 mL), and 4-methylmorpholine (3.6 mL, 32.8 mmol). The mixture was stirred at rt and monitored for completion by LC/MS. Upon reaction completion (ca. 3 hours) the mixture was added to water (50 mL) and the resulting mixture stirred at rt overnight. The mixture was then filtered, and the solids washed with water (10 mL). The solids were dried on house vacuum (ca. 17 torr) to afford (4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone (2.62 g, 85% yield) as a white solid containing 1.43 wt. % N-Methyl-2-pyrrolidinone.
The XRPD pattern of the crystalline Compound 1 Form C is depicted in
As shown by TGA and DSC curves in
Form X
Compound 1 Form X was prepared by the following procedure:
To a 50-mL, round-bottomed flask fitted with a nitrogen inlet and magnetic stir bar was added (4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone (5.0 g, 11.84 mmol) and acetonitrile (15 mL). To the mixture was added 1M HCl in water (15.00 mL, 15.00 mmol) with stirring. The homogeneous mixture was stirred at rt for 2 hours and then filtered through a fritted filter to remove insoluble material. The filtrate was cooled to 0° C. and 1M NaOH (15.00 mL, 15.00 mmol) was added at such a rate so as to maintain the temperature below 10° C. The mixture was stirred cold for 10 minutes and then allowed to warm to rt, during which time solids began to precipitate. The mixture was allowed to granulate overnight at rt. After overnight stirring (18 hours) the mixture was filtered, and the solids washed with water (15 mL). The material was dried on the filter under a nitrogen atmosphere followed by house vacuum (ca. 17 torr) to afford (4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl) benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone (4.47 g, 89% yield) as a white solid.
The XRPD pattern of the crystalline Compound 1 Form X is depicted in
As shown by TGA and DSC curves in
Form Z
Compound 1 Form Z was prepared by dissolving Compound 1 Mixture A in chloroform (CHCl3), followed by slow evaporation of the chloroform.
The XRPD pattern of the crystalline Compound 1 Form Z is depicted in
As shown by the DSC curve in
Slurry experiments with Mixture A were performed in two non-solvating solvents, EtOAc and ACN, at room temperature (RT) and 50° C. in order to evaluate the stability of Form B and Form X, which are two possible component forms of Mixture A. Mixture A was suspended in either EtOAc or ACN and stirred at either RT or 50° C., as indicated in Table 6, for 4 days. The solids collected were analyzed by XRPD to confirm the form change.
As summarized in Table 6 and
To evaluate the stability relationship between the hydrate Form C and the most stable anhydrate Form B, slurry competition experiments with Form B and Form C were conducted in different water activity (Aw) at RT. Form C was dissolved in three solvent mixtures (see Table 7) to get saturated solutions. Similar mass of Form B and Form C were added into the saturated solutions. The suspensions obtained were stirred at room temperature for 4 days and the solids collected were analyzed with XRPD.
As summarized in Table 7 and
Kinetic solubility and phase stability of Form B was tested in a formulation (0.5% methyl cellulose (MC) and 0.5% Tween 80 in water). The sample was monitored by XRPD at 1, 2, 4 and 24 hours for phase stability. As shown in
As summarized in Table 8 and
Compound 1 Form B can be formulated into a form (e.g., a capsule or unit dosage form) for oral use.
Compound 1 Form B was incorporated into a unit dosage form by encapsulation in capsules comprising hydroxypropyl methylcellulose (HPMC). The composition of the capsule comprising HPMC was selected to provide suitable resistance to hydroscopic active compounds, with a suitable resistance to moisture permeation, not prone to moisture variability (e.g., about 13-16% moisture content in a hard gelatin capsule shell). The oral unit dosage form can be a capsule containing a dose strength of 0.3 mg, 3 mg, or 9 mg.
Compound 1 Form B was formulated into capsules containing 1% w/v of Compound 1 Form B with other excipients in a 1 mL shell vial, as summarized in Table 9.
Compound 1 Form B was formulated via dry blending into capsules in size 4 hard gelatin capsules as summarized in Table 10.
Equivalents
Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation, numerous equivalents to the specific embodiments described specifically herein. Such equivalents are intended to be encompassed in the scope of the following claims.
This application claims the benefit of U.S. Provisional Application No. 62/752,229, filed Oct. 29, 2018, which is incorporated by reference in its entirety.
| Number | Name | Date | Kind |
|---|---|---|---|
| 5011928 | Venero et al. | Apr 1991 | A |
| 5510345 | Tuba et al. | Apr 1996 | A |
| 5759837 | Kuhajda et al. | Jun 1998 | A |
| 5856326 | Anthony et al. | Jan 1999 | A |
| 6080860 | Karimian et al. | Jun 2000 | A |
| 6410540 | Goehring et al. | Jun 2002 | B1 |
| 6469046 | Daines et al. | Oct 2002 | B1 |
| 6486192 | Daines et al. | Nov 2002 | B1 |
| 6486211 | Daines et al. | Nov 2002 | B1 |
| 6492368 | Dorsch et al. | Dec 2002 | B1 |
| 6498187 | Christensen, IV et al. | Dec 2002 | B1 |
| 6559179 | Gaitanopoulos et al. | May 2003 | B1 |
| 6608059 | Daines et al. | Aug 2003 | B1 |
| 6617317 | Adams et al. | Sep 2003 | B1 |
| 6670388 | Daines et al. | Dec 2003 | B1 |
| 6723749 | Christensen et al. | Apr 2004 | B2 |
| 6897207 | Cox et al. | May 2005 | B2 |
| 7309714 | Duffy et al. | Dec 2007 | B2 |
| 7375134 | Bayly et al. | May 2008 | B2 |
| 7459448 | Blackburn et al. | Dec 2008 | B2 |
| 7473688 | Bergstrom et al. | Jan 2009 | B2 |
| 7501407 | Castelhano et al. | Mar 2009 | B2 |
| 7504400 | Meerpoel et al. | Mar 2009 | B2 |
| 7511062 | Kuang et al. | Mar 2009 | B2 |
| 7601716 | Dorsey et al. | Oct 2009 | B2 |
| 7649012 | Kuhajda et al. | Jan 2010 | B2 |
| 7662826 | Seno et al. | Feb 2010 | B2 |
| 7671219 | Shigemitsu et al. | Mar 2010 | B2 |
| 7682857 | Hanamaki et al. | Mar 2010 | B2 |
| 7728153 | Smith et al. | Jun 2010 | B2 |
| 7763623 | Palani et al. | Jul 2010 | B2 |
| 7795284 | Galcera-Contour et al. | Sep 2010 | B2 |
| 7799826 | Smith et al. | Sep 2010 | B2 |
| 7807676 | Wang et al. | Oct 2010 | B2 |
| 7816360 | Meerpoel et al. | Oct 2010 | B2 |
| 7834015 | Jones et al. | Nov 2010 | B2 |
| 7919502 | Dorsey et al. | Apr 2011 | B2 |
| 7935694 | Blackburn et al. | May 2011 | B2 |
| 7943616 | Cox et al. | May 2011 | B2 |
| 7943620 | Harbeson et al. | May 2011 | B2 |
| 7973037 | Bayly et al. | Jul 2011 | B2 |
| 7977374 | Ferrigno et al. | Jul 2011 | B2 |
| 7998995 | Boren et al. | Aug 2011 | B2 |
| 8008301 | Beavers et al. | Aug 2011 | B2 |
| 8017637 | Galcera-Contour et al. | Sep 2011 | B2 |
| 8080561 | Dorsey et al. | Dec 2011 | B2 |
| 8088923 | Romo et al. | Jan 2012 | B2 |
| 8114880 | Meerpoel et al. | Feb 2012 | B2 |
| 8129398 | Beaulieu et al. | Mar 2012 | B2 |
| 8173629 | Singh et al. | May 2012 | B2 |
| 8188084 | Jones et al. | May 2012 | B2 |
| 8242129 | Tsuhako et al. | Aug 2012 | B2 |
| 8263633 | Blaquiere et al. | Sep 2012 | B2 |
| 9428464 | Courtney et al. | Aug 2016 | B2 |
| 9809552 | Staehle et al. | Nov 2017 | B2 |
| 10399951 | Bair et al. | Sep 2019 | B2 |
| 10450286 | Bair et al. | Oct 2019 | B2 |
| 10457655 | Bair et al. | Oct 2019 | B2 |
| 10472342 | Bair et al. | Nov 2019 | B2 |
| 20020115671 | Goehring et al. | Aug 2002 | A1 |
| 20030138432 | Glazier | Jul 2003 | A1 |
| 20030170244 | Pluenneke et al. | Sep 2003 | A1 |
| 20030220392 | Leber et al. | Nov 2003 | A1 |
| 20040001801 | Madison et al. | Jan 2004 | A1 |
| 20040022779 | Rudel et al. | Feb 2004 | A1 |
| 20040024050 | Smith et al. | Feb 2004 | A1 |
| 20040053931 | Cox et al. | Mar 2004 | A1 |
| 20040058988 | Christensen, IV et al. | Mar 2004 | A1 |
| 20040082786 | Zhu et al. | Apr 2004 | A1 |
| 20040122033 | Nargund et al. | Jun 2004 | A1 |
| 20050043300 | Middleton et al. | Feb 2005 | A1 |
| 20050240023 | Bayly et al. | Oct 2005 | A1 |
| 20050261292 | Antel et al. | Nov 2005 | A1 |
| 20050267304 | Cox et al. | Dec 2005 | A1 |
| 20050288213 | MacNeil et al. | Dec 2005 | A1 |
| 20060040906 | Bakshi et al. | Feb 2006 | A1 |
| 20060100194 | Blackburn et al. | May 2006 | A1 |
| 20060106062 | Kuang et al. | May 2006 | A1 |
| 20060128963 | Sings et al. | Jun 2006 | A1 |
| 20060148721 | Erondu | Jul 2006 | A1 |
| 20060160834 | Fong et al. | Jul 2006 | A1 |
| 20060270650 | MacNeil et al. | Nov 2006 | A1 |
| 20070010513 | Aslanian et al. | Jan 2007 | A1 |
| 20070032529 | Takagi et al. | Feb 2007 | A1 |
| 20070099884 | Erondu et al. | May 2007 | A1 |
| 20070112000 | Barton et al. | May 2007 | A1 |
| 20070142394 | Solomon et al. | Jun 2007 | A1 |
| 20070161615 | Andrews et al. | Jul 2007 | A1 |
| 20070167435 | Mutahi et al. | Jul 2007 | A1 |
| 20070173495 | Palani et al. | Jul 2007 | A1 |
| 20070191383 | Meerpoel et al. | Aug 2007 | A1 |
| 20070203236 | Smith et al. | Aug 2007 | A1 |
| 20070208087 | Sanders et al. | Sep 2007 | A1 |
| 20070244186 | Galcera-Contour et al. | Oct 2007 | A1 |
| 20070249579 | Wang et al. | Oct 2007 | A1 |
| 20080032972 | Dorsey et al. | Feb 2008 | A1 |
| 20080064632 | Amatruda et al. | Mar 2008 | A1 |
| 20080139572 | Wang et al. | Jun 2008 | A1 |
| 20080166378 | Schimmer et al. | Jul 2008 | A1 |
| 20080188529 | Bayly et al. | Aug 2008 | A1 |
| 20080200376 | MacCoss et al. | Aug 2008 | A1 |
| 20080207569 | Spada | Aug 2008 | A1 |
| 20080207605 | Spada | Aug 2008 | A1 |
| 20080242677 | Dehmlow et al. | Oct 2008 | A1 |
| 20080269234 | Gandhi et al. | Oct 2008 | A1 |
| 20080312247 | Gant et al. | Dec 2008 | A1 |
| 20080318969 | Harbeson et al. | Dec 2008 | A1 |
| 20090048276 | Goulet et al. | Feb 2009 | A1 |
| 20090082560 | Kobayashi et al. | Mar 2009 | A1 |
| 20090105213 | Blackburn et al. | Apr 2009 | A1 |
| 20090105305 | Butlin et al. | Apr 2009 | A1 |
| 20090111789 | Bartkovitz et al. | Apr 2009 | A1 |
| 20090118332 | Butlin et al. | May 2009 | A1 |
| 20090156591 | Ferrigno et al. | Jun 2009 | A1 |
| 20090163545 | Goldfarb | Jun 2009 | A1 |
| 20090176765 | Jones et al. | Jul 2009 | A1 |
| 20090197863 | Chu et al. | Aug 2009 | A1 |
| 20090197894 | Fu et al. | Aug 2009 | A1 |
| 20090209523 | Jones et al. | Aug 2009 | A1 |
| 20090253677 | Beaulieu et al. | Oct 2009 | A1 |
| 20090264402 | Jaehne et al. | Oct 2009 | A1 |
| 20090264416 | Ho et al. | Oct 2009 | A1 |
| 20090275624 | Galcera-Contour et al. | Nov 2009 | A1 |
| 20090286778 | Combs et al. | Nov 2009 | A1 |
| 20090325877 | Grunt et al. | Dec 2009 | A1 |
| 20090325980 | Meerpoel et al. | Dec 2009 | A1 |
| 20100029621 | Cooke et al. | Feb 2010 | A1 |
| 20100048576 | Dorsey et al. | Feb 2010 | A1 |
| 20100069367 | Boren et al. | Mar 2010 | A1 |
| 20100125075 | Pratt et al. | May 2010 | A1 |
| 20100135954 | Tsuhako et al. | Jun 2010 | A1 |
| 20100160290 | Kobayashi et al. | Jun 2010 | A1 |
| 20100190856 | Colomer Bosch et al. | Jul 2010 | A1 |
| 20100305121 | Smith et al. | Dec 2010 | A1 |
| 20100317658 | Galcera-Contour et al. | Dec 2010 | A1 |
| 20110039820 | Blackburn et al. | Feb 2011 | A1 |
| 20110076291 | Blaquiere et al. | Mar 2011 | A1 |
| 20110105389 | Hoveyda et al. | May 2011 | A1 |
| 20110124021 | Medghalchi | May 2011 | A1 |
| 20110160204 | Dorsey et al. | Jun 2011 | A1 |
| 20110172230 | Ishii et al. | Jul 2011 | A1 |
| 20110230446 | Bayly et al. | Sep 2011 | A1 |
| 20110274654 | Bahadoor et al. | Nov 2011 | A1 |
| 20110274655 | Bahadoor et al. | Nov 2011 | A1 |
| 20120004260 | Ossovskaya et al. | Jan 2012 | A1 |
| 20120015958 | Cooke et al. | Jan 2012 | A1 |
| 20120021976 | Boyle et al. | Jan 2012 | A1 |
| 20120122842 | Curtin et al. | May 2012 | A1 |
| 20120149683 | Cox et al. | Jun 2012 | A1 |
| 20120156138 | Smith | Jun 2012 | A1 |
| 20120178739 | Blackburn et al. | Jul 2012 | A1 |
| 20120195961 | Kritikou et al. | Aug 2012 | A1 |
| 20120196851 | Varrone et al. | Aug 2012 | A1 |
| 20120208827 | Dock et al. | Aug 2012 | A1 |
| 20120264737 | Oslob et al. | Oct 2012 | A1 |
| 20140329795 | Courtney et al. | Nov 2014 | A1 |
| 20150051211 | Ji et al. | Feb 2015 | A1 |
| 20160002188 | Bair | Jan 2016 | A1 |
| 20170312273 | Millan | Nov 2017 | A1 |
| 20180050997 | Bair et al. | Feb 2018 | A1 |
| 20180370933 | Bair et al. | Dec 2018 | A1 |
| 20190241532 | Bair et al. | Aug 2019 | A1 |
| 20190241533 | Bair et al. | Aug 2019 | A1 |
| 20200017458 | Bair et al. | Jan 2020 | A1 |
| Number | Date | Country |
|---|---|---|
| 2260767 | Jan 1998 | CA |
| 2391534 | May 2001 | CA |
| 2447023 | Nov 2002 | CA |
| 2492225 | Jan 2004 | CA |
| 2609957 | Jan 2007 | CA |
| 2634250 | Jul 2007 | CA |
| 2634847 | Jul 2007 | CA |
| 2637717 | Aug 2007 | CA |
| 2668094 | May 2008 | CA |
| 2696053 | Sep 2008 | CA |
| 2759098 | Oct 2010 | CA |
| 2764526 | Dec 2010 | CA |
| 2778990 | May 2011 | CA |
| 1272107 | Mar 2000 | CN |
| 101203510 | Jun 2008 | CN |
| 101384553 | Mar 2009 | CN |
| 101400682 | Apr 2009 | CN |
| 101426777 | May 2009 | CN |
| 101668520 | Mar 2010 | CN |
| 102372698 | Mar 2012 | CN |
| 102627610 | Aug 2012 | CN |
| 103420890 | Dec 2013 | CN |
| 0922099 | Jun 1999 | EP |
| 1073891 | Feb 2001 | EP |
| 1164374 | Dec 2001 | EP |
| 1255567 | Nov 2002 | EP |
| 1290446 | Mar 2003 | EP |
| 1397360 | Mar 2004 | EP |
| 1401469 | Mar 2004 | EP |
| 1465631 | Oct 2004 | EP |
| 1482924 | Dec 2004 | EP |
| 1534074 | Jun 2005 | EP |
| 1545572 | Jun 2005 | EP |
| 1751131 | Feb 2007 | EP |
| 1764616 | Mar 2007 | EP |
| 1807102 | Jul 2007 | EP |
| 1814879 | Aug 2007 | EP |
| 1831209 | Sep 2007 | EP |
| 1884513 | Feb 2008 | EP |
| 1896453 | Mar 2008 | EP |
| 1926721 | Jun 2008 | EP |
| 1966143 | Sep 2008 | EP |
| 1976848 | Oct 2008 | EP |
| 1976854 | Oct 2008 | EP |
| 1981341 | Oct 2008 | EP |
| 2019091 | Jan 2009 | EP |
| 2074103 | Jul 2009 | EP |
| 2076494 | Jul 2009 | EP |
| 2091951 | Aug 2009 | EP |
| 2139877 | Jan 2010 | EP |
| 2142533 | Jan 2010 | EP |
| 2144604 | Jan 2010 | EP |
| 2170802 | Apr 2010 | EP |
| 2233486 | Sep 2010 | EP |
| 2274288 | Jan 2011 | EP |
| 2445506 | May 2012 | EP |
| 2483277 | Aug 2012 | EP |
| 2485728 | Aug 2012 | EP |
| 2493310 | Sep 2012 | EP |
| 2493910 | Sep 2012 | EP |
| 2503890 | Oct 2012 | EP |
| 2829766 | Mar 2003 | FR |
| 100637955 | Oct 2006 | KR |
| 20080080201 | Sep 2008 | KR |
| 20080087833 | Oct 2008 | KR |
| 20080091814 | Oct 2008 | KR |
| 2194044 | Dec 2002 | RU |
| 2011108493 | Mar 2011 | RU |
| WO 1994002466 | Feb 1994 | WO |
| WO 1996030343 | Oct 1996 | WO |
| WO 1998003648 | Jan 1998 | WO |
| WO 1999016751 | Apr 1999 | WO |
| WO 1999054728 | Oct 1999 | WO |
| WO 1999064446 | Dec 1999 | WO |
| WO 2000022909 | Apr 2000 | WO |
| WO 2000078309 | Dec 2000 | WO |
| WO 2000078310 | Dec 2000 | WO |
| WO 2001014362 | Mar 2001 | WO |
| WO 2001014363 | Mar 2001 | WO |
| WO 2001014364 | Mar 2001 | WO |
| WO 2001017942 | Mar 2001 | WO |
| WO 2001030752 | May 2001 | WO |
| WO 2001030775 | May 2001 | WO |
| WO 2001036003 | May 2001 | WO |
| WO 2001090099 | Nov 2001 | WO |
| WO 2001096873 | Dec 2001 | WO |
| WO 2002000620 | Jan 2002 | WO |
| WO 2002000646 | Jan 2002 | WO |
| WO 2002002119 | Jan 2002 | WO |
| WO 2002009651 | Feb 2002 | WO |
| WO 2002009688 | Feb 2002 | WO |
| WO 2002024197 | Mar 2002 | WO |
| WO 2002026745 | Apr 2002 | WO |
| WO 2002055661 | Jul 2002 | WO |
| WO 2002080952 | Oct 2002 | WO |
| WO 2002095007 | Nov 2002 | WO |
| WO 2003000688 | Jan 2003 | WO |
| WO 2003024956 | Mar 2003 | WO |
| WO 2004009015 | Jan 2004 | WO |
| WO 2004014370 | Feb 2004 | WO |
| WO 2004030637 | Apr 2004 | WO |
| WO 2004037800 | May 2004 | WO |
| WO 2004050022 | Jun 2004 | WO |
| WO 2004110368 | Dec 2004 | WO |
| WO 2004110375 | Dec 2004 | WO |
| WO 2005000217 | Jan 2005 | WO |
| WO 2005009950 | Feb 2005 | WO |
| WO 2005016344 | Feb 2005 | WO |
| WO 2005035534 | Apr 2005 | WO |
| WO 2005046685 | May 2005 | WO |
| WO 2005073186 | Aug 2005 | WO |
| WO 2005085226 | Sep 2005 | WO |
| WO 2005097740 | Oct 2005 | WO |
| WO 2005097746 | Oct 2005 | WO |
| WO 2005097750 | Oct 2005 | WO |
| WO 2005110413 | Nov 2005 | WO |
| WO 2005116006 | Dec 2005 | WO |
| WO 2005116009 | Dec 2005 | WO |
| WO 2006021801 | Mar 2006 | WO |
| WO 2006032322 | Mar 2006 | WO |
| WO 2006034341 | Mar 2006 | WO |
| WO 2006049933 | May 2006 | WO |
| WO 2006051202 | May 2006 | WO |
| WO 2006060461 | Jun 2006 | WO |
| WO 2006067311 | Jun 2006 | WO |
| WO 2007002057 | Jan 2007 | WO |
| WO 2007029035 | Mar 2007 | WO |
| WO 2007033175 | Mar 2007 | WO |
| WO 2007038669 | Apr 2007 | WO |
| WO 2007049532 | May 2007 | WO |
| WO 2007068620 | Jun 2007 | WO |
| WO 2007068641 | Jun 2007 | WO |
| WO 2007075629 | Jul 2007 | WO |
| WO 2007075688 | Jul 2007 | WO |
| WO 2007080140 | Jul 2007 | WO |
| WO 2007082840 | Jul 2007 | WO |
| WO 2007087204 | Aug 2007 | WO |
| WO 2007089634 | Aug 2007 | WO |
| WO 2007092065 | Aug 2007 | WO |
| WO 2007130468 | Nov 2007 | WO |
| WO 2007137955 | Dec 2007 | WO |
| WO 2007138351 | Dec 2007 | WO |
| WO 2007138355 | Dec 2007 | WO |
| WO 2008011453 | Jan 2008 | WO |
| WO 2008030891 | Mar 2008 | WO |
| WO 2008052658 | May 2008 | WO |
| WO 2008059214 | May 2008 | WO |
| WO 2008061399 | May 2008 | WO |
| WO 2008066789 | Jun 2008 | WO |
| WO 2008073825 | Jun 2008 | WO |
| WO 2008075064 | Jun 2008 | WO |
| WO 2008075070 | Jun 2008 | WO |
| WO 2008075077 | Jun 2008 | WO |
| WO 2008099000 | Aug 2008 | WO |
| WO 2008106166 | Sep 2008 | WO |
| WO 2008106167 | Sep 2008 | WO |
| WO 2008109175 | Sep 2008 | WO |
| WO 2008133273 | Nov 2008 | WO |
| WO 2008133955 | Nov 2008 | WO |
| WO 2008157751 | Dec 2008 | WO |
| WO 2009000864 | Dec 2008 | WO |
| WO 2009004356 | Jan 2009 | WO |
| WO 2009064927 | May 2009 | WO |
| WO 2009098282 | Aug 2009 | WO |
| WO 2009099736 | Aug 2009 | WO |
| WO 2009132202 | Oct 2009 | WO |
| WO 2009143404 | Nov 2009 | WO |
| WO 2009151910 | Dec 2009 | WO |
| WO 2010017055 | Feb 2010 | WO |
| WO 2010056309 | May 2010 | WO |
| WO 2010120262 | Oct 2010 | WO |
| WO 2010138589 | Dec 2010 | WO |
| WO 2010150100 | Dec 2010 | WO |
| WO 2011035018 | Mar 2011 | WO |
| WO 2011036284 | Mar 2011 | WO |
| WO 2011042145 | Apr 2011 | WO |
| WO 2011053821 | May 2011 | WO |
| WO 2011056635 | May 2011 | WO |
| WO 2011066211 | Jun 2011 | WO |
| WO 2011103546 | Aug 2011 | WO |
| WO 2011140190 | Nov 2011 | WO |
| WO 2011140296 | Nov 2011 | WO |
| WO 2011163612 | Dec 2011 | WO |
| WO 2011163619 | Dec 2011 | WO |
| WO 2012016217 | Feb 2012 | WO |
| WO 2012019430 | Feb 2012 | WO |
| WO 2012037298 | Mar 2012 | WO |
| WO 2012037299 | Mar 2012 | WO |
| WO 2012064632 | May 2012 | WO |
| WO 2012064642 | May 2012 | WO |
| WO 2012071562 | May 2012 | WO |
| WO 2012092442 | Jul 2012 | WO |
| WO 2012096928 | Jul 2012 | WO |
| WO 2012101013 | Aug 2012 | WO |
| WO 2012122391 | Sep 2012 | WO |
| WO 2012125521 | Sep 2012 | WO |
| WO 2012130166 | Oct 2012 | WO |
| WO 2012151451 | Nov 2012 | WO |
| WO 2012151452 | Nov 2012 | WO |
| WO 2013028445 | Feb 2013 | WO |
| WO 2013028495 | Feb 2013 | WO |
| WO 2013033068 | Mar 2013 | WO |
| WO 2013045413 | Apr 2013 | WO |
| WO 2013060636 | May 2013 | WO |
| WO 2013064083 | May 2013 | WO |
| WO 2013078771 | Jun 2013 | WO |
| WO 2013156608 | Oct 2013 | WO |
| WO 2014044356 | Mar 2014 | WO |
| WO 2014146747 | Sep 2014 | WO |
| WO 2014164749 | Oct 2014 | WO |
| WO 2014164767 | Oct 2014 | WO |
| WO 2015014446 | Feb 2015 | WO |
| WO 2016205590 | Dec 2016 | WO |
| WO 2016205633 | Dec 2016 | WO |
| WO 2017189613 | Nov 2017 | WO |
| Entry |
|---|
| Aicher, T.D., et al., Secondary Amides of ®-3,3,3-Trifluoro-2-hydroxy-2-methylpropionic Acid as Inhibitors of Pyruvate Dehydrogenase Kinase, J. Med. Chem., 43: 236-249 (2000). |
| Berod, Luciana, et al., “De novo fatty acid synthesis controls the fate between regulatory T and T helper 17 cells,” Nature Medicine, vol. 20, No. 11, Nov. 2014. 1327-1335. |
| Clayden, Greeves, Warren and Wothers, Summary: The Three Major Approaches to the Synthesis of Aromatic Heterocycles, Aromatic heterocycles 2: synthesis, Organic Chemistry, Oxford University Press, 44: 1214-1215 (2001). |
| Database Registry [Online] Chemical Abstracts Service, Columbus, Ohio, US; Database accession No. 1387900-07-3 (Aug. 8, 2012); Database accession No. 1014245-05-6 (Apr. 13, 2008); and, Database accession No. 927570-20-5 (Mar. 20, 2007). 1 page. |
| Database Registry [Online] Chemical Abstracts Service, Columbus, Ohio, US; Database accession No. 1630806-71-1 (Oct. 29, 2014); Database accession No. 1630806-69-7 (Oct. 29, 2014); Database accession No. 1630806-63-1 (Oct. 29, 2014); Database accession No. 1630806-59-5 (Oct. 29, 2014); Database accession No. 1630806-56-2 (Oct. 29, 2014); Database accession No. 1630806-55-1 (Oct. 29, 2014); Database accession No. 1630806-49-3 (Oct. 29, 2014); Database accession No. 1630806-44-8 (Oct. 29, 2014); Database accession No. 1630806-41-5 (Oct. 29, 2014); Database accession No. 871002-005-0 (Jan. 3, 2006). |
| De Schrijver, et al., RNA Interference-mediated Silencing of the Fatty Acid Synthase Gene Attenuates Growth and induces Morphological Changes and Apoptosis of LNCaP Prostate Cancer Cells, Cancer Res (2003) 63:3799-3804. |
| Endo, Yusuke, et al., “Obesity Drives Th17 Cell Differentiation by Inducing the lipid Metabolic Kinase, ACC1,” Cell Reports, 12, Aug. 11, 2015, 1042-1055. |
| Fako, V.E., et al., Mechanism of Orlistat Hydrolysis by the Thioesterase of Human Fatty Acid Synthase, ACS Catal, 4: 3444-3453 (2014). |
| Fatima, S., et al., Molecular docking and 3D-QSAR studies on inhibitors of DNA damage signaling enzyme human PARP-1, Journal of Receptors and Signal Transduction, 32(4): 214-224 (2012). |
| Ferrigno, F., et al., Development of substituted 6-[4-fluoro-3-(piperazin-1-ylcarbonyl)benzyl]-4,5-dimethylpyridazin-3(2H)-ones as potent poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors active in BRCA deficient cells, Bioorganic & Medicinal Chemistry Letters, 20(3): 1100-1105 (2010). |
| First Formal Official Action: Colombian Patent Application No. 15-242.983, dated Dec. 17, 2015. |
| First Formal Official Action: Cuban Patent Application No. 2015-0120, dated Dec. 3, 2015. |
| Flavin, R., et al., Fatty acid synthase as a potential therapeutic target in cancer, Future Oncol, 6(4): 551-562 (2010). |
| Gansler TS, et al., Increased expression of fatty acid synthase {OA-519} in ovarian neoplasms predicts shorter survival. Hum. Pathol. (1997) 28 (6): 686-92. |
| Heaton, et al., Dengue virus nonstructural protein 3 redistributes fatty acid synthase to sites of viral replication and increases cellular fatty acid synthesis. Proc. Natl. Acad. Sci., (210) 107(40): 17345-17350. |
| Harriman, Geraldine, et al., “Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats,” PNAS Early Edition, 1-10. |
| Harrison, Stephen a., et al., “Orlistat in the Treatment of NASH: A Case Series,” the American Journal of Gastroenterology, vol. 98, No. 4, 2003, 926-930. |
| Harrison, S.A., et al., “A pilot study of orlistat treatment in obese, non-alchoholic steatohepatitis patients,” Aliment Pharmacol Ther, 2004, 20, 623-628. |
| Hunt DA, et al., Mrna stability and overexpression of fatty acid synthase inhuman breast cancer cell lines. Anticancer Res. (2007) 27{1A): 27-34. |
| International Search Report for PCT/US2014/023388, 4 pages (dated Aug. 18, 2014). |
| International Search Report for PCT/US2017/029469, 4 pages (dated Jun. 24, 2017). |
| International Search Report for PCT/US2019/058601, 9 pages (dated Jan. 16, 2020). |
| Jones, S.F. And Infante, J.R., Molecular Pathways: Fatty Acid Synthase, Clin Cancer Res; 21(24): 5434-5438 (2015). |
| Kant, Shiva, et al., “Myelopoietic Efficacy of Orlistat in Murine Hosts Bearing T Cell Lymphoma: Implication in Macrophage Differentiation and Activation,” PLOS One, Dec. 2013, vol. 8, Issue 12, e82396, 1-14. |
| Kridel, et al., Orlistat Is a Novel Inhibitor of Fatty Acid Synthase with Antitumor Activity, Cancer Res (2004) 54:2070-2075. |
| Kuhajda FP, Fatty acid synthase an dcancer: New application of an old pathway. Cancer Research, (2006) 66(12):5977-5980. |
| Li, et al., Fatty acid synthase expression is induced by the Epstein-Barr virus immediate-early protein BRLF1 and is required for lytic viral gene expression. Journal of Virology, (2004) 78(8):4197-4206. |
| Martin, Matthew W., et al., “Discovery and optimization of novel piperazines as potent inhibitors of fatty acid synthase (FASN),” Bioorganic & Medicinal Chemistry Letters, 29, 2019, 1001-1006. |
| Menear, K.A., et al., 443-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1, Journal of Medicinal Chemistry, 51(20), 6581-6591 (2008). |
| Menendez JA and Lupu R, Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis, Nature Review Cancer, (2007) 7: 763-777. |
| Montgomery, J.I., et al., Discovery and SAR of benzyl phenyl ethers as inhibitors of bacterial phenylalanyl-tRNA synthetase, Bioorganic & Medicinal Chemistry Letters, 19(3): 665-669 (2009). |
| Munger, et al., Systems-level metabolic flux profiling identifies fatty acid synthesis as a target for antiviral therapy. Nature Biotechnology, (2008) 26: 1179-1186. |
| Notice of First Formal Official Action: Panama Patent Application No. P1/2015/90868-01, dated Dec. 21, 2015. |
| Oliveras, et al., Novel anti-fatty acid synthase compounds with anti-cancer activity in HER2+breast cancer, Ann. N. Acad. Sci. (2010) 1210: 86-93. |
| Rassmann, et al., The human fatty acid synthase: a new therapeutic target for coxackievirus B3-induced diseases? Antiviral Research, (2007) 76: 150-158. |
| Rhee, H-K., et al., Synthesis and cytotoxicity of 2-phenylquinazolin-4(3)-one derivatives, European Journal of Medicinal Chemistry, 46(9): 3900-3908 (2011). |
| Samsa, et al., Dengue virus capsid protein usurps lipid droplets for viral particle formation. PLoS Pathegens, (2009) 5 10):e1000632. |
| Smagris, Eriks, “Pnpla3l148M Knockin Mice Accumulate PNPLA3 on Lipid Droplets and Develp Hepatic Steatosis,” Hepatology, vol. 61, No. 1, 2015, 108-118. |
| Vazquez, et al., Discovery of GSK837149A, an inhibitor of human fatty acid synthase targeting the b-ketoacyl reductase reaction, FEBS Journal (20008) 275:1556-1567. |
| Written Opinion for PCT/US17/29469 from the International Searching Authority dated Oct. 2, 2017. |
| Xenical_Orlistat_Prescribing_Infomation insert. Genentech, 2015, Reference ID: 3803457. |
| Yang, W., et al, Fatty acid synthase is up-regulated during hepatitis C virus infection and regulates hepatitis C virus entry and production. Hepatology (2008) 48, 13967-1403. |
| Zhang, et al., b-Lactam congeners of orlistat as inhibitors of fatty acid synthase, Bioorg. Med. Chem. Let. 18 491-2494 (2008). |
| Number | Date | Country | |
|---|---|---|---|
| 20200131155 A1 | Apr 2020 | US |
| Number | Date | Country | |
|---|---|---|---|
| 62752229 | Oct 2018 | US |
